Press Releases

Aug 31, 2022
NEW YORK , Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
Aug 02, 2022
NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
May 25, 2022
NEW YORK , May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated
May 10, 2022
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of
Oct 19, 2021
NEW YORK , Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,
Oct 14, 2021
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated